Skip to main content
ABIVAX logo

ABIVAX - Investor Relations & Filings

Listed IPO Jun 2015
Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 913 across all filing types
Latest filing 2026-07-24 Major Shareholding Noti…
Country FR France
Listing PA ABVX · 11 venues

Key figures FY2025

Period ended 2025-12-31 · EUR
Headline annual figures for ABIVAX, fiscal year 2025, reported in EUR, with the source filing for each figure.
Total Revenues EUR 4.60M per the Earnings Release filed 2026-03-23
Net Income EUR -336.10M per the Earnings Release filed 2026-03-23
Total Assets EUR 584.30M per the Earnings Release filed 2026-03-23
Total Equity EUR 455.20M per the Earnings Release filed 2026-03-23
Cash from Ops EUR -161.10M per the Earnings Release filed 2026-03-23

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Franchissement de seuil
Major Shareholding Notification Classification · 100% confidence The document is titled 'Franchissement de seuil' and refers to Article L. 233-7 of the French commercial code. It is an official declaration that Sofinnova Partners crossed below the 5% voting rights threshold in the company ABIVAX. According to the filing definitions, a notification of changes in significant share ownership levels (crossing thresholds) corresponds precisely to the Major Shareholding Notification (MRQ) category.
2026-07-24 French
Abivax renforce ses capacités commerciales avec des nominations stratégiques à des postes clés
Board/Management Information Classification · 95% confidence The document announces strategic executive appointments within Abivax's commercial team (such as Global Head of Marketing, Global Head of Patient Services, etc.) in preparation for product commercialization. According to the filing definitions, announcements regarding changes in senior management are classified under Board/Management Information (MANG).
2026-07-23 French
Abivax renforce ses capacites commerciales avec des nominations strategiques a des postes cles
Board/Management Information Classification · 95% confidence The document announces strategic executive appointments to Abivax's commercial leadership team (such as Global Head of Marketing, Global Head of Patient Services, etc.) in preparation for future commercialization. According to the definitions, announcements of changes in the company's board of directors or senior management fall under the 'Board/Management Information' (MANG) category.
2026-07-23 French
Franchissements de seuils
Major Shareholding Notification Classification · 100% confidence The document is an official notice detailing the crossing of shareholding thresholds (declarations de franchissements de seuils under article L. 233-7 of the commercial code) by JP Morgan Chase & Co. in the company ABIVAX. This content directly matches the definition of a Major Shareholding Notification (MRQ).
2026-07-21 French
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is titled 'Déclaration de franchissement de seuils' and details how JPMorgan Chase & Co. crossed the 5% threshold of capital and voting rights in Abivax. This matches the definition of a Major Shareholding Notification (MRQ), which reports changes in significant share ownership levels.
2026-07-21 French
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is a formal notification of a change in shareholding (threshold crossing) by JP Morgan Chase & Co. regarding the company ABIVAX. This is a standard regulatory disclosure required under French commercial law (article L. 233-7). According to the provided filing definitions, notifications of changes in significant share ownership levels are classified as 'Major Shareholding Notification' (MRQ).
2026-07-21 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.